Safety and immunogenicity of an anti-zika virus DNA vaccine

New England Journal of Medicine

Volumn 385, Issue 12, 2021, Pages

  Tebas, Pablo ^a   Roberts, Christine C ^d   Muthumani, Kar ^b   Reuschel, Emma L ^b   Kudchodkar, Sagar B ^b   Zaidi, Faraz I ^b   White, Scott ^c   Khan, Amir S ^c   Racine, Trina ^e   Choi, Hyeree ^b   Boyer, Jean ^c   Park, Young K ^d   Trottier, Sylvie ^e   Remigio, Celine ^d   Krieger, Diane ^f   Spruill, Susan E ^d   Bagarazzi, Mark ^c   Kobinger, Gary P ^e   Weiner, David B ^b   Maslow, Joel N ^d,g  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c Inovio Pharmaceuticals   (United States)

^d GeneOne Life Science Inc   (South Korea)

^e LAVAL UNIVERSITY   (Canada)

^f MIAMI RESEARCH ASSOCIATES   (United States)

^g MORRISTOWN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON RECEPTOR; GLS 5700 VACCINE; UNCLASSIFIED DRUG; ZIKA VIRUS VACCINE; DNA VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARRHYTHMOGENESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFICACY; DRUG SAFETY; ELECTROPORATION; ERYTHEMA; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HYPERHIDROSIS; HYPESTHESIA; HYPOTENSION; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MALAISE; MALE; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRURITUS; PULSED ELECTRIC FIELD; SKIN REDNESS; SWELLING; UPPER RESPIRATORY TRACT INFECTION; VERO CELL LINE; VIRUS NEUTRALIZATION; VIRUS STRAIN; ZIKA FEVER; ADVERSE EVENT; ANIMAL; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; MIDDLE AGED; MOUSE; MULTICENTER STUDY; PHYSIOLOGY; T LYMPHOCYTE; VACCINE IMMUNOGENICITY; ZIKA VIRUS;

ADULT; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNOGENICITY, VACCINE; INJECTIONS, INTRADERMAL; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; T-LYMPHOCYTES; VACCINES, DNA; VIRAL VACCINES; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85115301430     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1708120     Document Type: Article

References (33)

1. Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg 1952; 46: 509-20.
2. Duffy MR, Chen T-H, Hancock WT, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 2009; 360: 2536-43.
3. Cao-Lormeau VM, Roche C, Teissier A, et al. Zika virus, French Polynesia, South Pacific, 2013. Emerg Infect Dis 2014; 20: 1085-6.
4. Campos GS, Bandeira AC, Sardi SI. Zika virus outbreak, Bahia, Brazil. Emerg Infect Dis 2015; 21: 1885-6.
5. Fauci AS, Morens DM. Zika virus in the Americas - yet another arbovirus threat. N Engl J Med 2016; 374: 601-4.
6. Brasil P, Calvet GA, Siqueira AM, et al. Zika virus outbreak in Rio de Janeiro, Brazil: clinical characterization, epidemiological and virological aspects. PLoS Negl Trop Dis 2016; 10(4): e0004636.
7. Parra B, Lizarazo J, Jimenez-Arango JA, et al. Guillain-Barre syndrome associated with Zika virus infection in Colombia. N Engl J Med 2016; 375: 1513-23.
8. Mlakar J, Korva M, Tul N, et al. Zika virus associated with microcephaly. N Engl J Med 2016; 374: 951-8.
9. Paz-Bailey G, Rosenberg ES, Doyle K, et al. Persistence of Zika virus in body fluids - final report. N Engl J Med 2018; 379: 1234-43.
10. Foy BD, Kobylinski KC, Chilson Foy JL, et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerging Infect Dis 2011; 17: 880-2.
11. D'Ortenzio E, Matheron S, Yazdanpanah Y, et al. Evidence of sexual transmission of Zika virus. N Engl J Med 2016; 374: 2195-8.
12. Musso D, Nhan T, Robin E, et al. Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. Euro Surveill 2014; 19(14): e20761.
13. Motta IJF, Spencer BR, Cordeiro da Silva SG, et al. Evidence for transmission of Zika virus by platelet transfusion. N Engl J Med 2016; 375: 1101-3.
14. Filipe AR, Martins CM, Rocha H. Laboratory infection with Zika virus after vaccination against yellow fever. Arch Gesamte Virusforsch 1973; 43: 315-9.
15. Muthumani K, Griffin BD, Agarwal S, et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. NPJ Vaccines 2016; 1: 16021 (https://www.nature.com/articles/npjvaccines201621).
16. Kalams SA, Parker SD, Elizaga M, et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 2013; 208: 818-29.
17. Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 2015; 386: 2078-88.
18. Anfasa F, Siegers JY, van der Kroeg M, et al. Phenotypic differences between Asian and African lineage Zika viruses in human neural progenitor cells. mSphere 2017; 2(4): e00292-17.
19. Lazear HM, Govero J, Smith AM, et al. A mouse model of Zika virus pathogenesis. Cell Host Microbe 2016; 19: 720-30.
20. Zhang NN, Tian M, Deng YQ, et al. Characterization of the contemporary Zika virus in immunocompetent mice. Hum Vaccin Immunother 2016; 12: 3107-9.
21. Davis BS, Chang G-JJ, Cropp B, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001; 75: 4040-7.
22. Abbink P, Larocca RA, De La Barrera RA, et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 2016; 353: 1129-32.
23. Larocca RA, Abbink P, Peron JPS, et al. Vaccine protection against Zika virus from Brazil. Nature 2016; 536: 474-8.
24. Pardi N, Hogan MJ, Pelc RS, et al. Zika virus protection by a single lowdose nucleoside-modified mRNA vaccination. Nature 2017; 543: 248-51.
25. Maslow JN. Vaccine development for emerging virulent infectious diseases. Vaccine 2017; 35: 5437-43.
26. Hirao LA, Draghia-Akli R, Prigge JT, et al. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis 2011; 203: 95-102.
27. Bagarazzi ML, Yan J, Morrow MP, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012; 4(155): 155ra138.
28. WHO/UNICEF Zika virus (ZIKV) vaccine target product profile (TPP): vaccine to protect against congenital Zika syndrome for use during an emergency. February 2017 (http://www.who.int/immunization/research/development/WHO-UNICEF-Zikavac-TPP-Feb2017.pdf).
29. Vogt MR, Dowd KA, Engle M, et al. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complementdependent effector mechanisms. J Virol 2011; 85: 11567-80.
30. Shedlock DJ, Aviles J, Talbott KT, et al. Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther 2013; 21: 1432-44.
31. Muthumani K, Falzarano D, Reuschel EL, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med 2015; 7(301): 301ra132.
32. Nigro G, Adler SP, La Torre R, Best AM. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005; 353: 1350-62.
33. Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 1994; 343: 1548-51.